Rockwell Medical Technologies, Inc. focuses on the development of unique renal drugs, including a lead drug, soluble ferric pyrophosphate (SFP), which provides iron via dialysate for dialysis patients. The company anticipates strong market potential in the chronic kidney disease sector, with significant cost savings and improved patient outcomes compared to current therapies. Forward-looking statements indicate a solid growth strategy with expected FDA approval and commercialization of SFP by 2011/2012.

1. Innovative Bio-pharmaceuticalCompany July 2009

2. 2Safe Harbor StatementThis presentation contains forward-looking statements. All statements, other than statements of historical facts, including, among others, statements regarding the Company’s future financial position, business strategy, projected levels of growth, projected costs and projected financing needs, are forward-looking statements. Those statements include statements regarding the intent, belief or current expectations of Rockwell Medical Technologies, Inc. and members of the Company’s management team, as well as the assumptions on which such statements are based, and generally are identified by the use of words such as “may,” “will,“ “seeks,” “anticipates,” “believes,” “estimates,” “expects,” “plans,” “intends,” “should” or similar expressions. Forward looking statements are not guarantees of future performance and involve risks and uncertainties that actual results may differ materially from those contemplated by such forward-looking statements.The company believes these forward-looking statements are reasonable; however, undue reliance should not be placed on any forward-looking statements, which are based on current expectations. All written and oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by these cautionary statements. Further, forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time unless required by law.

3. Agenda3

4. Corporate Overview4

5. 5Corporate SummaryBio-pharmaceutical drug company with established operating businessDevelopment of unique, proprietary renal drugsLead drug iron delivery via dialysate – new standard of care Expect superior patient outcomes vs. current therapiesWomen’s health, oncology and parenteral nutritionStrong, growing core operating renal businessBroad distribution channel and manufacturing base3 manufacturing plants; 27% U.S. market shareDialysate; removes toxins and replaces nutrients in blood Products needed to maintain human lifeProvided 16.6 million+ treatments in 2008

6. 6Kidney Disease MarketChronic kidney disease (CKD) 19.2 million Progressive loss of renal function; 5-StagesEnd Stage Renal Disease (ESRD) – irreversible loss of kidney function  need dialysis to liveStage 5 = 395,000 US patients; 2 million worldwideStages 3 and 4 = 8.1 million US patientsSteady, growing market unaffected by economiesCausesDiabetes and obesity, CVD, hypertension, agingCurrent treatment optionsDialysis: life-saving blood filtering treatmentKidney transplant

7. Lead Drug CandidateSFPSoluble Ferric Pyrophosphate7

8. SFP – Iron via Dialysate8 Dialysis Dialyzer Blood flows through Dialyzer membrane

9. Dialysate flows outside of membrane in opposite direction

10. Nutrients (Ca, K, Mg, Na) delivered into blood while toxins and waste are removed

11. SFP (iron) now delivered into blood via dialysate just like nutrients

12. Replaces kidney function

13. Removes waste and excess fluids

14. Replenishes nutrients

15. 3-4 hour treatmentSFP – Iron via DialysateBio-available iron delivered directly to blood stream

16. Replaces iron in blood lost during each dialysis treatment

17. Rapid uptake of iron by transferrin

18. Transferrin takes iron to bone marrow

19. Maintains iron balance within target hemoglobin rangeInside Dialyzer Filter9

20. 10SFP AdvantagesPhysiological iron maintenance therapySlow infusion (10-15 µg/dL iron dose) via dialysate during scheduled dialysis session; 3X per week; works like dietary ironSmall dose replaces 5-7mg avg blood loss per sessionMaintains iron balance  efficiently matches EPO and hemoglobinSuperior safety benefits for patient + lowers provider costSafely travels direct to bloodstream  bypasses liver and avoids toxicity~2000 Clinical Doses to Date  No Adverse ReactionsSignificantly lowers IV iron administration costs eliminates needles, syringes and RN time Bundled reimbursement provides superior patient-outcome at lowest cost; significant EPO savings expected Market potentialU.S. IV iron CKD $500 million ($430M+ ESRD)Global IV iron CKD $850 millionU.S. dialysis concentrates $180 million

21. Maximizes ErythropoiesisBy maintaining constant iron balance SFP maximizes creation of red blood cells, generation of hemoglobin and optimization of EPO treatment response11

22. SFP vs IV IronHemodialysis Dependent Chronic kidney Disease (HDD-CKD)12* high molecular weight sugar molecules have been linked to anaphylactic reactions; not present in SFP

23. SFP Development Program13

24. SFP Phase IIb StudyPrimary Endpoint: Drop in hemoglobin of 1 gm/dL or more and safety.Secondary Endpoints: Time taken to drop hemoglobin by 1 g/dL or more, increase in hemoglobin to more than 12.5 g/dL, reticulocyte hemoglobin, infection, iron transferred into the patient.Enrollment completed April 2009Two positive Data Safety Monitoring Board (DSMB) reviews to date; validates SFP superior safety profileExpect data Q4 2009 / Q1 201014

25. SFP Commercial Launch: 2012 15Strategy: Leverage captive client relationships and distribution channels for fast SFP penetration* Forecast

26. Intellectual PropertyRockwell owns exclusive worldwide licensePatents issued in U.S, Europe and Japan  three largest ESRD markets in the worldIron delivery via dialysate in hemodialysis (HD) and peritoneal dialysis (PD)Composition of matter and method of delivery Patent expires 2021 (including 5 year Hatch-Waxman)Patent filed on SFP-GMP grade formulationTo cover dialysis, oral OTC/Rx, TPN, Oncology, and other extensions16

27. Financial Overview17